Klin Farmakol Farm. 2019;33(1):19-24 | DOI: 10.36290/far.2019.032

Use of anti‑VEGF drugs in ophthalmology

Alexandr Stepanov, Jan Studnička
Katedra očního lékařství, Lékařská fakulta v Hradci Králové, Univerzita Karlova
Oční klinika, Fakultní nemocnice Hradec Králové

Intravitreal injections of antibodies blocking VEGF (Vascular Endothelial Growth Factor) are an effective treatment for the wet form of age‑related macular degeneration, macular edema in retinal vein occlusion, diabetic macular edema, and choroidal neovascular membranes in less frequent macular diseases. A blockade of VEGF leads to interference of the permeability of retinal and choroidal blood vessels, angiogenesis, cytokine production and influences the inflammatory response. There are currently 2 approved anti‑VEGF drugs (ranibizumab and aflibercept), with a multicentre, randomized, clinical trial showing a positive clinical effect as well as a good safety profile.

Keywords: ranibizumab, aflibercept, bevacizumab, diabetic macular edema, retinal vein occlusion, age‑relatedmacular degeneration,anti‑VEGF

Received: November 2, 2017; Accepted: November 2, 2017; Published: April 25, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Stepanov A, Studnička J. Use of anti‑VEGF drugs in ophthalmology. Klin Farmakol Farm. 2019;33(1):19-24. doi: 10.36290/far.2019.032.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Chalam KV, Brar VS, Murthy RK. Human ciliary epithelium as a source of synthesis and secretion of vascular endothelial growth factor in neovascular glaucoma. JAMA Ophthalmol 2014; 132(11): 1350-1354. Go to original source...
    2. Kaur C, Foulds WS, Ling E-A. Hypoxia-ischemia and retinal ganglion cell damage. Clin Ophthalmol 2008; 2(4): 879-889. Go to original source...
    3. Kim M, Lee C, Payne R, Yue BYJT, Chang J-H, Ying H. Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: a review. Surv Ophthalmol 2015; 60(6): 524-535. Go to original source...
    4. Ng EWM, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5(2): 123-132. Go to original source... Go to PubMed...
    5. Narayanan R, Kuppermann BD, Jones C, Kirkpatrick P. Ranibizumab. Nat Rev Drug Discov 2006; 5(10): 815-816. Go to original source... Go to PubMed...
    6. De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med 2012; 44(1): 1-9. Go to original source...
    7. Stewart MW, Grippon S, Kirkpatrick P. Aflibercept. Nat Rev Drug Discov. 2012; 11(4): 269-270. Go to original source... Go to PubMed...
    8. Ellis LM. Bevacizumab. Nat Rev Drug Discov. 2005; Suppl: S8-S9. Go to original source... Go to PubMed...
    9. Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 2007; 85(4): 425-430. Go to original source... Go to PubMed...
    10. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis 2012; 15(2): 171-185. Go to original source... Go to PubMed...
    11. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57(20): 4593-4599. Go to PubMed...
    12. Yang J, Wang X, Fuh G, Yu L, Wakshull E, Khosraviani M, et al. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. Mol Pharm 2014; 11(10): 3421-3430. Go to original source...
    13. Yu L, Liang XH, Ferrara N. Comparing protein VEGF inhibitors: In vitro biological studies. Biochem Biophys Res Commun 2011; 408(2): 276-281. Go to original source... Go to PubMed...
    14. Ahn SJ, Ahn J, Park S, Kim H, Hwang DJ, Park JH, et al. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes. Invest Ophthalmol Vis Sci 2014; 55(1): 567-573. Go to original source... Go to PubMed...
    15. Niwa Y, Kakinoki M, Sawada T, Wang X, Ohji M. Ranibizumab and aflibercept: intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaque eyes. Invest Ophthalmol Vis Sci 2015; 56(11): 6501-6505. Go to original source... Go to PubMed...
    16. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008; 146(4): 508-512. Go to original source...
    17. Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 2012; 154(4): 682-686.e2. Go to original source... Go to PubMed...
    18. Do D. Oral presentation at 11th Congress of the Asia-Pacific Vitreo-retina Society (APVRS); Kuala Lumpur, Malaysia, December 2017: 8-10.
    19. Stewart MW. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev Clin Pharmacol 2014; 7(2): 167-180. Go to original source...
    20. Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol 2014; 158(3): 532-536. Go to original source...
    21. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 2014; 98(12): 1636-1641. Go to original source...
    22. Seddon JM, Chen CA. The epidemiology of age-related macular degeneration. Int Ophthalmol Clin 2004; 44: 17-39. Go to original source...
    23. Studnička J. Ranibizumab (Lucentis) v léčbě věkem podmíněné makulární degenerace. Čes. a slov. Oftal. 2009; 65(3): 107-111
    24. Berger JW, Fine SL, Maguire MG. Age-related Macular Degeneration. Mosby, Inc., New York, 1999: 463 s.
    25. Boguszaková J. Věkem podmíněná makulární degenerace. Prakt Lék 2001; 81: 310-314.
    26. Landy J, Brown GC. Update on Photodynamic Therapy. Curr Opin Ophthalmol 2003; 14: 163-168. Go to original source... Go to PubMed...
    27. Visudyne(R), product monograph, third edition, Chameleon Medical Communications Ltd, London, 2003: 92 s.
    28. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med 2006; 355 (14): 1432-1444. Go to original source... Go to PubMed...
    29. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419-1431. Go to original source... Go to PubMed...
    30. Spaide R. Ranibizumab according to need: a treatment for agerelated macular degeneration. Am J Ophthalmol 2007; 143(4): 679-680. Go to original source...
    31. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007; 144(4): 627-637. Go to original source... Go to PubMed...
    32. Řehák J, Studnička J. Doporučené postupy pro diagnostiku a léčbu pacientů s venózní okluzí sítnice. Čes. a slov. Oftal. 2012; 68(6): 244-256.
    33. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012; 119(4): 802-809. Go to original source... Go to PubMed...
    34. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118(10): 2041-2049. Go to original source... Go to PubMed...
    35. Pielen A, Clark WL, Boyer DS, et al. Integrated results from the COPERNICUS and GALILEO studies. Clin Ophthalmol 2017; 11: 1533-1540. Go to original source... Go to PubMed...
    36. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology 2015; 122(3): 538-544. Go to original source...
    37. Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: literatura review. Curr Med Res Opin 2010; 26: 1587-1597. Go to original source...
    38. Studnička J. Aflibercept v léčbě diabetického makulárního edému. Čes. a slov. Oftal. 2015; 71(5): 243-246.
    39. Sosna T, Švancarová R, Netuková M, et al. Současný pohled na diabetický makulární edém. Čes a slov Oftal 2012; 3: 91-96.
    40. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33(11): 2399-2405. Go to original source...
    41. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2009; 116(11): 2175-2181.e1. Go to original source... Go to PubMed...
    42. Korobelnik J-F, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121(11): 2247-2254. Go to original source...
    43. Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE Study Group. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 2014; 121(3): 682-692.e2. Go to original source... Go to PubMed...
    44. Lai TYY, Staurenghi G, Lanzetta P, et al. MINERVA study group. Efficacy and safety of ranibizumab for the treatement of choroidal neovascularization due to uncommon cause: Twelve-Month Results of the MINERVA Study. Retina 2018; 38(8): 1464-1477. Go to original source...
    45. Al-Latayfeh M, Silva PS, Sun JK, Aiello LP. Antiangiogenic therapy for ischemic retinopathies. Cold Spring Harb Perspect Med 2012; 2(6): a006411-a006411. Go to original source... Go to PubMed...
    46. Bahar I, Yeung SN, Sella R, Slomovic A. Anterior segment uses of bevacizumab. Curr Opin Ophthalmol 2012; 23(4): 303-316. Go to original source... Go to PubMed...
    47. Xiong Q, Li Z, Li Z, Zhu Y, Abdulhalim S, Wang P, et al. Anti-VEGF agents with or without antimetabolites in trabeculectomy for glaucoma: a meta-analysis. PLoS ONE 2014; 9(2): e88403. Go to original source... Go to PubMed...
    48. Al-Latayfeh M, Silva PS, Sun JK, Aiello LP. Antiangiogenic therapy for ischemic retinopathies. Cold Spring Harb Perspect Med 2012; 2(6): a006411-a006411. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.